SCHEMBL6005274

SCHEMBL6005274

[O]S(=O)(=O)Nc1cccc2ccccc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.71
RECQL P46063 1/20 0.67
ALDH1A1 P00352 4/20 0.59
KDM4E B2RXH2 3/20 0.59
HPGD P15428 2/20 0.59
HSD17B10 Q99714 2/20 0.59
KMT2A Q03164 4/20 0.57
MAPT P10636 4/20 0.57
MEN1 O00255 3/20 0.57
GAA P10253 2/20 0.52
CYP3A4 P08684 2/20 0.50
TP53 P04637 1/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
CDC25B P30305 1/20 0.50
ATM Q13315 1/20 0.50
LMNA P02545 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MCL1 Q07820 1/20 0.48
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4465085 0.88 KEAP1 (0.67) KEAP1RECQLALDH1A1KDM4EHPGD
SCHEMBL10780391 0.87 KEAP1 (0.71) KEAP1RECQLALDH1A1KDM4EHPGD
SCHEMBL2124660 0.83 KEAP1 (1.00) KEAP1RECQLALDH1A1KDM4EHPGD
SCHEMBL29254256 0.83 KEAP1 (0.67) KEAP1RECQLALDH1A1KDM4EHPGD
SCHEMBL45616 0.83 KEAP1 (0.67) KEAP1RECQLALDH1A1KDM4EHPGD
SCHEMBL11793189 0.83 KEAP1 (0.67) KEAP1RECQLALDH1A1KDM4EHPGD
SCHEMBL7441407 0.83 KEAP1 (0.67) KEAP1RECQLALDH1A1KDM4EHPGD
SCHEMBL4465089 0.83 KEAP1 (0.67) KEAP1RECQLALDH1A1KDM4EHPGD
SCHEMBL18638259 0.83 KEAP1 (0.67) KEAP1RECQLALDH1A1KDM4EHPGD
SCHEMBL11405633 0.82 KEAP1 (0.65) KEAP1RECQLALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 KEAP1 176/4885RECQL 4070/4885ALDH1A1 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.